Business
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and d
About this update from Sangamo Therapeutics, Inc.
[{"type":"image","alt":"Sangamo Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Sangamo Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/dc00e2ffd577d3c5ddd72548c6e29e7f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yqjv.8GrNgvCZN5FGKWCtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/dc00e2ffd577d3c5ddd72548c6e29e7f","width":300,"height":74}},"lazy":false},{"type":"text","content":"RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology.","length":548,"tagName":"p"},{"type":"text","content":"“ASGCT is an important forum for showcasing innovation in gene and cell therapy, and we look forward to presenting advances in our neurology pipeline, alongside the strength of our genome engineering platform,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “These data will demonstrate the potency, versatility and specificity of our neurology epigenetic regulation capabilities, as well as the promise of our MINT platform to integrate large DNA payloads into the genome – an approach that may expand the possibilities for treating complex diseases.”","length":573,"tagName":"p"},{"type":"text","content":"Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets – specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo’s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internal...